Study guide

2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models

Key Takeaways Explain This Topic AI

Empiric risks come from observed recurrence in studied families, not from segregation arithmetic — they are the correct tool when no single-gene mechanism is established.

Multifactorial recurrence rises with more affected relatives, closer relationship, greater severity or bilaterality, consanguinity, and an affected member of the less-commonly affected sex (the Carter effect).

Carrier-probability models (BRCAPRO, PREMM5, MMRpro) answer "how likely is a pathogenic variant?" while cancer-risk models (Gail, Claus, Tyrer-Cuzick, BOADICEA/CanRisk) answer "how likely is the disease?" — the exam tests whether you pick the right output.

The Gail model uses limited first-degree family history and is not appropriate for strong pedigrees, known pathogenic variant carriers, or prior lobular carcinoma in situ.

NCCN-style breast MRI discussions use a lifetime risk threshold of about 20% calculated by models that are largely dependent on family history, such as Tyrer-Cuzick, Claus, or BOADICEA — not by the Gail model.

Last updated: August 2026

2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models

Quick Answer: When no single-gene mechanism is established, use empiric risk — observed recurrence in studied families. Multifactorial recurrence rises with more affected relatives, closer relationship, greater severity, consanguinity, and affection of the less-susceptible sex (Carter effect) . Named models split into carrier-probability tools (BRCAPRO, PREMM5, MMRpro) and absolute-risk tools (Gail, Claus, Tyrer-Cuzick, BOADICEA/CanRisk); choosing the wrong class is the classic error.

Domain 2A gives 17 scored items to risk assessment, and only some of them are Mendelian or Bayesian. ABGC also lists a task statement about evaluating the applicability of reference resources, risk assessment tools, position statements, and practice guidelines — which is a direct instruction to know what each model can and cannot do.

Empiric risk: what it is and when to use it

An empiric risk is derived from observed recurrence in families ascertained through an affected proband, not from calculating gamete segregation. Use it when:

The condition is multifactorial (neural tube defects, cleft lip/palate, most isolated congenital heart disease, autism, schizophrenia).

The mechanism is heterogeneous and no molecular diagnosis was found.

A chromosomal event is sporadic (recurrence after a de novo trisomy).

Germline mosaicism makes an apparently de novo dominant condition carry a small nonzero recurrence.

Empiric figures are population- and study-dependent , so counsel them as ranges tied to a source rather than as exact constants. Commonly cited sibling recurrence ranges for an otherwise unremarkable family with one affected child:

  • Condition Commonly cited sibling recurrence Note
  • Neural tube defect ~2–5% (varies by population and folate status) Preconception folic acid changes the number
  • Cleft lip ± palate (isolated) ~4% Higher with bilateral or more severe clefting
  • Isolated congenital heart defect ~2–4% Lesion-specific; left-sided obstructive lesions run higher
  • Autism spectrum disorder ~10–20% Higher in multiplex families and for male siblings
  • Schizophrenia ~9–10% for a sibling Rises sharply with two affected first-degree relatives
  • Clubfoot (isolated) ~2–5% Sex-influenced

Do not memorize these as fixed exam constants. Board stems that require a number usually supply it; what is scored is whether you recognize that an empiric figure — not 1/4 or 1/2 — is the right kind of answer.

The multifactorial threshold model

Liability to a multifactorial trait is normally distributed in the population; individuals whose liability exceeds a threshold are affected. Relatives of an affected person have a liability distribution shifted toward the threshold, which is why recurrence is elevated but far below Mendelian values.

Five modifiers raise recurrence, and every one of them shows up in exam vignettes:

Number of affected relatives. Two affected siblings shifts the family further right than one; recurrence roughly doubles or more.

Degree of relationship. Risk falls sharply from first-degree to second- to third-degree relatives — a much steeper fall-off than the halving seen in dominant inheritance.

Severity of the defect. Bilateral cleft lip and palate implies higher family liability than unilateral cleft lip alone.

Consanguinity. Shared background liability alleles raise recurrence for multifactorial as well as recessive conditions.

Sex of the affected proband — the Carter effect. When a condition affects one sex more often, an affected member of the less commonly affected sex implies a higher liability load in the family and therefore higher recurrence for relatives. The classic teaching example is infantile pyloric stenosis , which is more common in males: relatives of an affected female proband carry the higher recurrence risk.

Trap: reversing the Carter effect. The intuitive but wrong answer is that the more commonly affected sex signals more risk. It is the opposite — affection in the rarer sex means the family needed more liability to cross a higher threshold.

Prevention as part of the risk conversation

Empiric risk counseling is incomplete without the modifiable lever. For neural tube defects, the standard preconception recommendation is 0.4 mg (400 µg) of folic acid daily for average-risk pregnancies , escalating to 4 mg (4,000 µg) daily beginning at least one month before conception and through the first trimester for a person with a prior NTD-affected pregnancy. Naming both figures, and the timing, is the counseling half of the item.

Named risk-assessment models

The most-missed distinction in this subdomain is what the model outputs .

Model Output Inputs it actually uses Where it fails

Gail / BCRAT 5-year and lifetime breast cancer risk Age, menarche, age at first live birth, biopsies, atypical hyperplasia, number of affected first-degree relatives, race/ethnicity Ignores paternal and second-degree history, age at relatives' diagnosis, ovarian cancer; not valid for known pathogenic variant carriers, prior LCIS/DCIS, or prior chest radiation

Claus Breast cancer risk First- and second-degree family history with ages at diagnosis Family-history only; no hormonal or biopsy inputs

Tyrer-Cuzick (IBIS) Breast cancer risk and a carrier probability Extended family history, hormonal/reproductive factors, BMI, benign breast disease, breast density in later versions Can overestimate in some validation cohorts; garbage-in from unverified pedigrees

BOADICEA / CanRisk Breast and ovarian risk and carrier probability Extended pedigree, panel gene results, polygenic risk score, risk factors, ancestry Requires detailed pedigree data; ancestry-specific validation still evolving

BRCAPRO Probability of carrying a BRCA1/2 pathogenic variant Pedigree with affected/unaffected relatives and ages Says nothing directly about cancer risk in a non-carrier

PREMM5 Probability of carrying an MMR or EPCAM pathogenic variant (Lynch) Personal and family history of Lynch-spectrum cancers with ages A prediction tool, not a diagnosis; tumor MMR/MSI testing is a parallel pathway

MMRpro Probability of an MMR pathogenic variant Pedigree plus tumor MSI/IHC results when available Same caution: carrier probability, not cancer risk

Applying the right model, correctly

Guideline thresholds specify the model class. NCCN-style discussion of annual breast MRI uses a lifetime risk of roughly ≥20% calculated with models that are largely dependent on family history — Tyrer-Cuzick, Claus, or BOADICEA. Using a Gail score to clear or justify MRI is a documented misapplication, because Gail was never designed to capture a strong pedigree.

Verify the pedigree before you run anything. Every model inherits the errors of the family history fed into it. A "maternal aunt with ovarian cancer" that turns out to be cervical cancer can move a Tyrer-Cuzick output across a management threshold.

Do not apply a model outside its validated population. Most of these tools were developed and validated primarily in populations of European ancestry; their calibration in other ancestral groups is weaker, and that limitation belongs in the counseling.

A model output is not a test result. A 24% lifetime risk is a probability statement supporting a screening discussion, not a diagnosis, and a 6% BRCAPRO carrier probability does not exclude a pathogenic variant.

Model output can conflict with testing criteria. A patient can meet testing criteria while sitting below an MRI threshold, or vice versa. Answer the question that was asked.

Common traps

Applying a 1/4 or 1/2 Mendelian figure to an isolated multifactorial malformation.

Reversing the Carter effect .

Using Gail for a woman with two affected first-degree relatives and an affected paternal aunt.

Quoting a carrier-probability model output as the patient's cancer risk, or the reverse.

Presenting an empiric range as a precise constant without naming the source or population.

Forgetting the 4 mg folic acid escalation for a prior NTD-affected pregnancy and counseling the routine 0.4 mg dose instead.